Evommune (NYSE:EVMN) Shares Cross Above 50-Day Moving Average - Should You Sell?

Key Points

• Evommune shares rose 2.9% and moved above their 50-day moving average of $7.81, reaching $8.09 before last trading at $7.875 on volume of 843,159 shares.
• Analysts’ overall view is “Moderate Buy,” with a consensus price target of $30.80; recent ratings include one Strong Buy, ten Buys, four Holds, and one Sell.
• The stock remains well below its 200-day moving average of $17.28. Analyst targets vary widely, including a cut by Leerink Partners from $28 to $22 and targets of $18 and $30 from other firms.

Evommune, Inc. (NYSE:EVMN - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $7.81 and traded as high as $8.09. Evommune shares last traded at $7.8750, with a volume of 843,159 shares.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on EVMN. Leerink Partners decreased their target price on Evommune from $28.00 to $22.00 and set an "outperform" rating for the company in a research note on Wednesday, September 9th. Raymond James Financial set a $18.00 price target on shares of Evommune in a research note on Wednesday, September 9th. Weiss Ratings cut Evommune from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, September 11th. Stifel Nicolaus set a $30.00 price objective on Evommune in a research report on Wednesday, September 9th. Finally, HC Wainwright reiterated a "neutral" rating on shares of Evommune in a research report on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $30.80.

Evommune Trading Up 2.9%

The business's fifty day moving average is $7.81 and its 200 day moving average is $17.28. The firm has a market capitalization of $285.78 million and a P/E ratio of -0.71.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EVMN. Janus Henderson Group PLC acquired a new position in Evommune in the first quarter worth approximately $20,615,000. Defilade Capital Management L.P. lifted its stake in Evommune by 215.0% in the first quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company's stock valued at $15,601,000 after acquiring an additional 463,171 shares during the last quarter. Velan Capital Investment Management LP lifted its stake in Evommune by 1.1% in the second quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company's stock valued at $5,997,000 after acquiring an additional 5,000 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in Evommune in the first quarter valued at approximately $10,308,000. Finally, Stempoint Capital LP grew its position in Evommune by 184.1% in the first quarter. Stempoint Capital LP now owns 193,777 shares of the company's stock worth $4,385,000 after acquiring an additional 125,581 shares in the last quarter.

Evommune Company Profile

Evommune, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-mediated inflammatory diseases. The company's research is aimed at modulating dysregulated immune pathways that contribute to chronic inflammation, with the goal of developing treatments that may address significant unmet medical needs. Evommune is advancing a pipeline of investigational small-molecule and biologic therapies for inflammatory conditions. Its development programs are focused primarily on diseases affecting the skin and other tissues, including conditions such as atopic dermatitis and related immune-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.